Charles River Laboratories (CRL) reported Q1 EPS of $2.75, $0.03 better than the analyst estimate of $2.72. Revenue for the quarter came in at $913.9 million versus the consensus estimate of $910.1 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $11.50-$11.75, versus the consensus of $11.64.
- Revenue growth, reported 13.5% – 15.5%